Development of a Pharmacokinetic Model Describing Neonatal Fc Receptor‐Mediated Recycling of HL2351, a Novel Hybrid Fc‐Fused Interleukin‐1 Receptor Antagonist, to Optimize Dosage Regimen

HL2351 (hIL‐1Ra‐hyFc) is a novel recombinant protein formed by the fusion of two human interleukin‐1 receptor antagonist components into one antibody‐derived fragment crystallizable portion. Although HL2351 has a pharmacological mechanism of action similar to that of anakinra as a commercialized bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngo, Lien, Oh, Jaeseong, Kim, Anhye, Back, Hyun‐moon, Kang, Won‐ho, Chae, Jung‐woo, Yun, Hwi‐yeol, Lee, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577020/
https://www.ncbi.nlm.nih.gov/pubmed/32945613
http://dx.doi.org/10.1002/psp4.12555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577020/
https://www.ncbi.nlm.nih.gov/pubmed/32945613
http://dx.doi.org/10.1002/psp4.12555

Ejemplares similares